Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1

Conditions

Multiple Myeloma 27Recurrence 3Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Neoplasm, Residual 1Myasthenia Gravis 1Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21Standard of Care 20Sirolimus 20Azacitidine 20venetoclax 19Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × talquetamab × Clear all
NCT03399799 2026-05-08

MonumenTAL-1

Janssen Research & Development, LLC

Phase 1 Active not recruiting
279 enrolled 1 FDA
Other hematologic neoplasm

Hematologic Neoplasms

NCT04634552 2026-05-08

MonumenTAL-1

Janssen Research & Development, LLC

Phase 2 Recruiting
510 enrolled 1 FDA
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡